Skip to main content
Clinical Trials/JPRN-jRCTs071220071
JPRN-jRCTs071220071
Recruiting
Phase 2

Treatment protocol for adult acute lymphoblastic leukemia (-ALL/MRD2023-) - JSCT ALL/MRD2023

Koichi Akashi0 sites210 target enrollmentNovember 24, 2022

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
acute lymphoblastic leukemia
Sponsor
Koichi Akashi
Enrollment
210
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 24, 2022
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Koichi Akashi

Eligibility Criteria

Inclusion Criteria

  • 1\.Cases diagnosed with acute lymphocytic leukemia in the WHO classification (2017\) with more than 26% blasts in the bone marrow, or mixed phenotype acute leukemia (MPAL) in the WHO classification (2017\). Patients with more than 26% blasts in the bone marrow and undergoing ALL\-directed chemotherapy. The WHO classification (2017 edition) is used as the diagnostic criteria for MPAL in this study.
  • 3\.First\-time treatment patients who have not received chemotherapy or radiotherapy.
  • 3\.Patients aged between 16 and 65 years old.
  • 4\.Performance status (ECOG): 0 to 2 cases.
  • 5\.Cases without severe organ damage. T. Bil\=\<2\.0mg/dL, Cr\=\<2\.0mg/dL
  • 6\.Patients who have given written consent from the patient after explaining the content of this research. However, in the case of minors, written consent has been obtained from the legal representative and the individual.

Exclusion Criteria

  • 1\. Blast cell surface immunoglobulin\-positive Burkitt leukemia.
  • 2\.Patients with active double cancer.
  • 3\.Patients with difficult\-to\-control infections.
  • 4\. Cases with severe mental disorders.
  • 5\. Pregnant cases.
  • 6\.Other cases judged inappropriate by the attending physician.

Outcomes

Primary Outcomes

Not specified

Similar Trials